Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferiprone in pantothenate kinase-associated neurodegeneration (PKAN)
ISRCTN72904618Phase 3Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Jul 2013
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in pantothenate kinase-associated neurodegeneration (PKAN) comparing Deferiprone with Placebo (2 arms). Primary endpoint: Change in Barry-Albright Dystonia Scale total score. Started Jul 2013; status: completed.
02
Drugs
deferiprone
03
Conditions
pantothenate kinase-associated neurodegeneration (PKAN)
Beyond the preview
Go deeper on ISRCTN72904618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN72904618.